Measuring the activity of the disease in patients with cutaneous lupus erythematosus (original) (raw)
Related papers
Arthritis & Rheumatism, 2008
Methods. Fourteen subjects with cutaneous lupus erythematosus (CLE; n ؍ 10), a mimicker skin disease only (a cutaneous lesion that may appear clinically similar to CLE; n ؍ 1), or both (n ؍ 3) were rated with the CLASI by academic-based dermatologists (n ؍ 5) and rheumatologists (n ؍ 5). Results. The dermatology intraclass correlation coefficient (ICC) was 0.92 for activity and 0.82 for damage; for rheumatology the ICC was 0.83 for activity and 0.86 for damage. For intrarater reliability, the dermatology Spearman's rho was 0.94 for activity and 0.97 for damage; for rheumatology the Spearman's rho was 0.91 for activity and 0.99 for damage.
British Journal of Dermatology, 2010
Background In 2005, a scoring system (CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index) was developed for patients with cutaneous lupus erythematosus (CLE) to assess disease 'activity' and 'damage'. However, the CLASI does not give an accurate assessment of the severity in all disease subtypes. Objectives The main objective of this study was to analyse critically the included parameters of the CLASI and to revise the activity and damage score taking into account various clinical features of the different subtypes of CLE. The revised CLASI (RCLASI) was also validated for use in clinical trials. Patients and methods A RCLASI was designed with regard to the anatomical region (i.e. face, chest, arms) and morphological aspects (i.e. erythema, scaling ⁄hyperkeratosis, oedema ⁄infiltration, scarring ⁄atrophy) of skin lesions and evaluated by nine dermatologists who scored 12 patients with different subtypes of CLE to estimate inter-and intrarater reliability. Results Reliability studies demonstrated an intraclass correlation coefficient (ICC) for an inter-rater reliability of 0AE89 for the activity score [95% confidence interval (CI) 0AE79-0AE96] and of 0AE79 for the damage score (95% CI 0AE62-0AE92). The ICC for intrarater reliability for the activity score was 0AE92 (95% CI 0AE89-0AE95) and the ICC for the damage score was 0AE95 (95% CI 0AE92-0AE98). Conclusions In the present study, a RCLASI was developed by experts, and reliability studies supported the validity and applicability of the revised scoring instrument for CLE. Thus, the RCLASI is a valuable instrument in multicentre studies and for the clinical evaluation of activity and damage in different disease subtypes.
Rheumatology International, 1991
No single test allows an adequate measure of disease activity in multisystem diseases such as systemic lupus erythematosus (SLE). In order to evaluate the spectrum of manifestations of disease activity in SLE, investigators have developed numerous ad hoc scales which have not been tested for their validity or reliability. Three instruments have been extensively studied: the British Isles Lupus Activity Group instrument (BILAG), the SLE Disease Activity Index (SLEDAI), and the Systemic Lupus Activity Measure (SLAM). All three have been demonstrated to have convergent and construct validity when compared to the clinician's judgement. The summation of the number of criteria of the American Rheumatism Association (ARA) SLE criteria has been shown to be an inadequate measure of disease activity. Standardized measures of disease activity for SLE should enhance our ability to compare results from different centers in finer distinctions than dead or alive.
The Journal of Rheumatology, 2011
Objective. To test the interrater and intrarater reliability of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Responder Index (SRI-50), an index designed to measure ≥ 50% improvement in disease activity between visits in patients with systemic lupus erythematosus. Methods. This was a multicenter, cross-sectional study with raters from Canada, the United Kingdom, and Argentina. Patient profile scenarios were derived from real adult patients. Ten rheumatologists from university and community hospitals and postdoctoral rheumatology fellows participated. An SRI-50 data retrieval form was used. Each rheumatologist scored SLEDAI-2K at the baseline visit and SRI-50 on followup visit, for the same patients, on 2 occasions 2 weeks apart. Physician global assessment (PGA) was determined on a numerical scale at baseline visit and a Likert scale on followup visit. Interrater and intrarater reliability was assessed using intraclass correlation coefficient (ICC) and kappa statistics whenever applicable. Results. Forty patient profiles were created. The ICC performed on 80 patient profiles for interrater ranged from 1.00 for SLEDAI-2K and SRI-50 to 0.96 for PGA. The intrarater ICC for SLEDAI-2K, SRI-50, and PGA scores ranged from 1.00 to 0.86. Substantial agreement was determined for the interrater Likert scale, with a kappa statistic of 0.57. Conclusion. The SRI-50 is reliable to assess ≥ 50% improvement in lupus disease activity. Use of the SRI-50 data retrieval form is essential to ensure optimal performance of the SRI-50. SRI-50 can be used by both rheumatologists and trainees and performs equally well in trained as well as untrained rheumatologists.
Cutaneous lupus erythematosus — A study of clinical and laboratory prognostic factors in 65 patients
Irish Journal of Medical Science, 1995
An eleven year review of patients presenting with cutaneous lupus erythematosus (LE) was made in order to determine the frequency of change from discoid LE (DLE) to systemic LE (SLE) and to identify clinical and laboratory prognostic factors. Three of fifty-six (5.4%) patients with DLE progressed to SLE after 1, 13 and 34 years respectively. They had a progressive rash and persistent abnormalities in their full blood count, erythrocyte sedimentation rate, antinuclear antibody and serum immunoglobulins prior to the development of SLE. We recommend that regular longterm monitoring of these indices should be carried out in patients presenting with DLE.
Arthritis & Rheumatism, 2006
Methods. Patients with SLE were recruited from 11 centers. Two physician raters separately assessed the patients' disease activity using the BILAG-2004 index in routine clinical practice. Scores ranged from A (for very active disease) to E (for inactivity). Two reliability exercises were performed. Changes were made to the index after the first exercise (E1), and additional training was provided to the raters before the second exercise (E2). E1 and E2 involved 12 and 14 raters, respectively. Interrater reliability was assessed using kappa statistics and intraclass correlation coefficients. Levels of agreement and the extent of major disagreement were also examined. Major disagreement was defined as a score difference between raters of A versus C, D, or E or B versus D or E.
Arthritis Care & Research, 2011
Description Purpose-To assess lupus activity based upon the "intent-to-treat" premise. The original version was published in 1988 (19). Over time, several deficiencies were noted by members of BILAG, which prompted a major revision. The updated version (BILAG 2004) was published in 2005 (20). Content-Specific manifestation in 9 systems. In this revised index, the original section of vasculitis has been removed and 2 systems were added: ophthalmic and abdominal. Number of items-101 and 5 additional items required mainly for calculations ofglomerular filtration rate. Response options/scale-Each question is answered as: 0 = not present, 1 = improving, 2 = same, 3 = worse, and 4 = new. Recall period for items-It records disease activity occurring over the past 4 weeks as compared with the previous 4 weeks. ROMERO-DIAZ et al.
Lupus, 2011
The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a newly described tool used to assess the activity of and damage caused by cutaneous lupus erythematosus (CLE). There is a paucity of data on CLASI from the Indian subcontinent. We sought to determine the applicability of CLASI in specific lesions of CLE in patients with systemic lupus erythematosus (SLE) attending a tertiary care hospital in India. In this prospective, cross-sectional study, 93 patients of SLE with cutaneous lesions were recruited. CLASI activity and damage scores of lupus erythematosus (LE)-specific skin lesions were done in 75 patients with SLE. The mean CLASI activity score was 15.4 ± 9.4 (range 0–39) and the mean damage score was 6.87 ± 7.75 (range 0–30). Higher mean CLASI activity scores were seen in patients with a combination of acute, subacute and chronic CLE and in those with widespread lesions. Patients with longstanding disease and long duration of skin lesions had higher damage...
Arthritis & Rheumatism, 2007
Methods. Patients with SLE were recruited into a multicenter cross-sectional study. Data on SLE disease activity (scores on the BILAG-2004 index, Classic BILAG index, and Systemic Lupus Erythematosus Disease Activity Index 2000 [SLEDAI-2K]), investigations, and therapy were collected. Overall BILAG-2004 and overall Classic BILAG scores were determined by the highest score achieved in any of the individual systems in the respective index. Erythrocyte sedimentation rates (ESRs), C3 levels, C4 levels, anti-double-stranded DNA (anti-dsDNA) levels, and SLEDAI-2K scores were used in the analysis of construct validity, and increase in therapy was used as the criterion for active disease in the analysis of criterion validity. Statistical analyses were performed using ordinal logistic regression for construct validity and logistic regression for criterion validity. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated.